Galderma's Chief Science Officer has positioned early skin-care intervention as the clinical foundation for managing GLP-1-related facial changes—a shift that reframes the aesthetic practice's role from corrective to preventive. The guidance emphasizes establishing a robust skincare regimen before patients initiate GLP-1 therapy, rather than waiting for volume loss to manifest and then reaching for fillers.